Letters Withdrawal of sibutramine

Editorial is judgment in advance of the facts

BMJ 2010; 340 doi: http://dx.doi.org/10.1136/bmj.c1346 (Published 10 March 2010) Cite this as: BMJ 2010;340:c1346
  1. Nick Finer, consultant endocrinologist and honorary professor1
  2. On behalf of the Executive Steering Committee of the Sibutramine Cardiovascular Outcome Trial (SCOUT): Ian Caterson, Walmir Coutinho, Luc Van Gaal, Aldo Maggioni, Christian Torp-Pedersen, Arya Sharma, and Philip James.
  1. 1University College Hospitals London, London WC1T 7DN
  1. n.finer{at}ucl.ac.uk

    Williams’s negative, even nihilistic, approach to obesity treatment and to sibutramine in particular is ill judged and inaccurate.1 His editorial seems to be based mainly on the limited data from the Sibutramine Cardiovascular Outcomes Trial (SCOUT) released by the European Medicines Agency, and perhaps data not in the public domain. It would have been better to await full details of the trial findings before writing an editorial.

    To say …

    Sign in

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe